

August 10, 2020

Market Outlook

Indian markets are likely to open flat tracking mixed global cues and lack of any major trigger from Asian markets. However, import ban on defence equipment, verdict on staggered AGR payments for telcos and earning outcomes would be key monitorables for today's trade.

Markets Yesterday

- Domestic markets ended flattish amid mixed global cues and rising Covid-19 cases in the country
- US markets ended mixed as concerns surrounding US-China tensions and uncertainty about stimulus package offset better-than-expected unemployment data

Key Developments

- For Titan, we expect revenues from the jewellery, watches division to decline 55%, 88% YoY, respectively, in Q1FY21. Overall revenues are expected to fall 62% YoY to ₹ 1980.9 crore. We anticipate the company will report EBITDA loss of ₹ 7.5 crore. Management commentary on overall demand scenario and cost rationalisation measures will be key monitorables to watch
- Mahindra & Mahindra (M&M) reported a relatively healthy operational performance in Q1FY21. Standalone net sales for the quarter were at ₹ 5,602 crore. Standalone EBITDA in Q1FY21 was at ₹ 549 crore with corresponding EBITDA margins at 9.8% (down 261 bps QoQ). Consequent standalone PAT for the quarter came in at ₹ 112 crore, crimped by lower other income and higher interest costs.
- India's coal import fell 43% to 11.1 million tonnes (MT) in July 2020 on account of higher stockpile of dry fuel at pitheads, plants and ports. During April-July 2020, total coal imports were at 57.3 MT, which is 36% lower than 89.2 MT imported during April-July 2019

Nifty He	at Map								
Asian Paints	1,805 4.4%	Bajaj Finance	3,466 3.6%	UPL	480 3.6%	Indusind Bank	509 2.9%	Bajaj Finserv	6,469 2.8%
BPCL	420 2.6%	Britannia	3,934 2.0%	T ata Motors	119 2.0%	Maruti	6,680 1.8%	G AIL	97 1.4%
Zee Ent.	150 1.0%	Bharti Airtel	570 0.9%	Adani Ports	327 0.9%	ONGC	79 0.9%	T ata S teel	404 0.9%
Shree Cement	21,894 0.8%	C oal India	130 0.7%	Reliance Ind.	2,147 0.6%	Bharti Infratel	193 0.6%	Nestle	16,761 0.5%
Eicher	21,793 0.5%	G rasim Ind	637 0.4%	Bajaj Auto	3,002 0.4%	ITC	196 0.4%	TechM	662 0.4%
HDFC Bank	1,044 0.3%	Vedanta	123 0.3%	JS W S teel	240 0.2%	K otak Bank	1,342 0.2%	Axis Bank	433 0.0%
H ero Moto	2,706 0.0%	P ower G rid	176 0.0%	SBI	191 -0.2%	Hindalco	178 -0.2%	Dr R eddy	4,571 -0.3%
ICICI Bank	358 -0.4%	HUL	2,211 -0.4%	NTPC	86 -0.4%	C ipla	729 -0.4%	HDFC Ltd	1,778 -0.4%
TCS	2,295 -0.6%	Ultratech	4,005 -0.6%	L&T	916 -0.7%	Wipro	277 -0.8%	10 C	86 -0.9%
Sun Pharma	526 -1.2%	M&M	601 -1.5%	Infosys	951 -1.9%	HCI Tech	690 -2.2%	Titan	1,091 -2.6%

Today's Highlights

Results: Titan, Ipca Labs, Action Construction, BoB, Cochin Shipyard, Shree Cement, Caplin Point, D-link India, HEG, Sonata Software, TTK Prestige, Triveni Engineering, Oriental Carbon, KEC International



	Close	Previous	Ung (%)	WH D(%)	Y I D(%) P	/E (Tyrtwa)
Sensex	38,041	38,025	0.0	4.3	-18.0	20.6
Nifty	11,214	11,200	0.1	4.2	-18.0	20.1


Institutional Activity							
	CY18	CY19	YTD CY20	Yesterday	Last 5 Days		
FII (₹cr)	-68,503	40,893	-58,463	397	8,141		
DII (₹cr)	107,388	44,478	83,210	-439	-1,252		


World Indices – Monthly performance						
Kospi	Dow Jones	BSE	NSE	Nasdaq		
2,352	27,433	38,041	11,214	11,011		
9.4%	5.2%	4.2%	4.1%	3.7%		
G ermany	Nikkei	U.K.	France	Shanghai		
12,675	22,330	6,032	4,890	3,354		
0.3%	0.2%	-1.0%	-1.6%	-8.7%		

Commodities	Close	Previous	Chng (%)	MTD(%)	YTD(%)
G old (₹10 gm)	54,876	55,845	-1.7	3.3	42.1
Silver (₹kg)	74,483	76,052	-2.1	14.9	59.8
C rude (\$/barrel)	44.4	45.1	-1.5	4.2	-31.6
C opper (\$/tonne)	6,308	6,479	-2.6	1.2	5.7
Currency					
USD/INR	74.9	74.9	0.0	-0.2	-4.7
EUR/USD	1.2	1.2	-0.8	0.6	5.7
USD/YEN	105.9	105.6	0.4	0.3	2.9
ADRs					
HDFC Bank	46.5	46.3	0.5	-0.7	-26.8
ICICI Bank	9.6	9.6	0.0	1.1	-37.1
Tata Motors	7.9	7.9	0.9	14.7	-39.5
Infosys	12.6	12.8	0.1	-1.6	22.6
Dr Reddys Labs	60.8	61.2	-0.7	0.9	51.1
Wipro	4.2	4.3	-1.9	-1.4	13.6




Key Data Points			
Key Economic Indicator	Period	Latest	Prior Values
RBI Cash Reserve Ratio	N/A	3.00%	4.00%
RBIRepo Rate	N/A	4.00%	4.40%
RBI Reverse Repo Rate	N/A	3.35%	3.75%
CPIYY	Jun	6.09%	5.84%
Current Account Balance	Q 1	-0.6bln \$	-1.4bln \$
Exports - USD	Jun	21.91 bln\$	19.05 bln\$
FX Reserves, USD Final	Jun	517.64 bln\$	506.8 bln\$
GDP Quarterly yy	Q 1	3.10%	4.70%
GDP Annual	FY 20	4.20%	6.10%
Imports - USD	Jun	21.11 bln \$	22.2 bln \$
Industrial Output yy	Jun	-34.70%	-55.50%
Manufacturing Output	Jun	-39.30%	-64.30%
Trade Deficit Govt - USD	Jun	0.79 bln \$	3.15 bln \$
WPI Food yy	May	1.10%	2.60%
WPI Fuel yy	May	-19.83%	-10.12%
WPI Inflation yy	May	-3.12%	-
WPI Manuf Inflation yy	May	-0.42%	-





Corporate Action Tracker								
Security name	Action	Ex Date	Record Date	Status	Price (₹)			
Sun Pharma	Buyback			Ongoing	425.00			
Sterlite Technologies	Buyback			Ongoing	150.00			
Oriental Carbon	Dividend	11-Aug-20	-		6.00			
Dabur	Dividend	13-Aug-20	-		1.60			
Escorts	Dividend	13-Aug-20	-		2.50			
Maruti Suzuki	Dividend	13-Aug-20	-		60.0			
NTPC	Dividend	13-Aug-20	14-Aug-20)	2.65			
TTK Prestige	Dividend	13-Aug-20	-		20.00			
Haw kins Cooker	Dividend	14-Aug-20	17-Aug-20)	80.00			
Varun Beverages	Dividend	14-Aug-20	17-Aug-20)	2.50			



Company/ Industry	News	View	Impact
Divi's Lab	on the back of strong growth across segments. Generic segment grew 54.0% YoY to ₹894 crore. Carotenoids grew 19.8% YoY to ₹127 crore. Custom synthesis grew 48.9% YoY to ₹709 crore. EBITDA margins expanded 716 YoY, 847 bps QoQ to 40.5% (Idirect estimates: 32.5%) due to significantly better overall operational performance. Hence, EBITDA grew 80.8% YoY to ₹700	performance. Q1 results were better than I-direct estimates on all fronts. In addition to the strong quarterly performance, the important narrative for Divi's is the ongoing mega capex it has undertaken a few quarters back and is likely to complete by FY21. This massive capex amounting to ₹ 1800 crore would further augment the capacities thus preparing the company to tap growing opportunities. We expect the full-blown impact of this investment to fructify from FY22 onwards.	

Cipla	due to 15.9% YoY growth in domestic formulations to ₹ 1608 crore. US revenues declined 8.8% YoY to ₹ 1021 crore. RoW markets grew 53.1% YoY to ₹ 672 crore due to base effect. EU grew 19.4% YoY to ₹ 240 crore. EBITDA margins improved 145 bps YoY to 24.1% on account of a sharp drop in other expenditure amid Covid lockdown, partly offset by lower gross margins due to higher contribution from margin dilutive trade generics segment. Subsequently,	We continue to focus on the management's long-drawn strategy of targeting four verticals viz. One-India, South Africa & EMs, US generics & specialty and lung leadership. Recent first generic approval by USFDA for Albuterol sulphate (Proventil HFA) amid rise in demand for Albuterol products in the ongoing Covid-19 pandemic are vindication of its lung leadership quest. Across the board transformation from tenderised model to private model in exports market and towards rapid consumerisation of important TGx, Rx in India bode well to change the investors' perspective	
Bata India	impacted due to closure of stores for major period during quarter and absence of school shoes sale. Revenue fell 85% YoY to ₹ 135 crore. Despite a sharp reduction in operating overheads, EBITDA losses came	Aligning with the current demand scenario, Bata has tweaked its product portfolio by launch of collections such as fitness-athome, Easy-wash & Work-from Home. The company reiterated its vision of opening 500 franchisee stores by 2023 and reaching in new towns. We believe with its strong brand patronage and pan-India retail reach, Bata India should be able to revive its revenue growth trajectory as and when the impact of the Covid-19 is phased out	\Leftrightarrow
Abbott India	slowdown in some therapies amid Covid-19 lockdown. EBITDA margins improved 450 bps YoY to 21.9% due to lower travel and promotional spends partially offset by higher raw material costs. EBITDA grew 34.0% YoY to ₹ 233 crore. PAT grew 54.2% YoY to ₹ 180 crore on the back of better	Abbott posted a strong earnings performance despite Covid challenges. We remain positive on the company due to its robust and sustainable business model backed by stable growth, debt-free B/S, favourable market dynamics with doctor prescription stickiness and lower perceived risk factors. We continue to believe in Abbott's strong growth track in power brands and capability of new launches on a fairly consistent basis	
Amara Raja Batteries (ARBL)	performance in Q1FY21. Net sales for the quarter fell 37% YoY to ₹ 1,151 crore. EBITDA in Q1FY21 was at ₹ 152 crore with corresponding EBITDA margins at 13.2%,	ARBL's performance was slightly better than its key competitor, possibly tracking higher share of replacement channel in overall mix. Management commentary was positive on automotive aftermarket demand as well as industrial segments (UPS and telecom sector)	
Container corporation of India	revenue front while lower on the profitability front. Revenues de-grew 27% YoY to ₹ 1189 crore, led by volume de-growth of 21%. EBITDA margins de-grew 1123 bps YoY to 13.4% mainly due to higher other	expectations, EBITDA margins saw an exceptional contraction. For the quarter, the company recorded ₹ 121 crore as land license fee (LLF) for all terminals in other expenses, as per the new policy of railways applicable from April 1, 2020 (rent payable at 6% value of the land), which has negatively impacted the operational performance	P



Kajaria Ceramics	as expected, impacted by Covid-19 led lockdown. Sales volumes declined by 61% YoY while topline de-grew 60% YoY to ₹ 277.6 crore. The company reported EBITDA loss of ₹ 7.6 crore on account of negative operating leverage. Weakness at the	While it will be a weak FY21, recovery is tracking better than expected. In Q2, the company has indicated that capacity utilisation improved to 78% in July, 2020 (vs. ~26% in June, 2020) and further stands at 85%+ in August, 2020. In terms of sales, the current sales volumes are back to 80% of Q2FY20 levels and the company expects it to improve progressively, going ahead. Kajaria, with a net cash balance sheet and superior brand, is likely to tide over the challenging times and even capitalise on market share gain during the recovery phase.	\Leftrightarrow
Sobha Ltd	as expected, owing to Covid-19 impact. Sales volume at 6.50 lakh was down 38.9% YoY with sales value down 37.3% YoY at 487.7 crore. On the financial front, revenues were		\Leftrightarrow
Shipping Corporatio n of India	topline grew 24% YoY to ₹1143 crore, led by 51% jump in the Tanker revenues (75% of		
DCB Bank	numbers. Moratorium book as on June 2020 reduced sharply to ~26% as against ~60% in April 2020. Provision surged 106% YoY to ₹84 crore, including Covid provisions of ₹32		

EBITDA/tonne of ₹949/tonne for the guarter that came as positive surprise. Hence, weak performance due to lockdown impact is cushioned to some extent by cost control

measures.

ICICI Securities | Petail Research





Balrampur Chini

Balrampur Chini reported strong set of The company has exported ~2.8 lakh tonnes distillery in January 2020. Moreover, better inventory by November-December Moreover, quarter. quarter. Operating margins was down 330 bps We remain positive on the stock mainly due to gross margin contraction. Average sugar realisation has been lower compared to last year given sugar prices fell to ₹31/kg in April & May due to lockdown conditions imposed across country. Net profit grew by 24.9% to ₹139.5 crore

numbers with 50.8% increase in revenues & of sugar in current sugar season. Moreover, it 24.9% increase in net profit. The higher has been able to sell higher sugar quantities in Revenue was higher was on account of 60% domestic market through higher sale quota. increase in both sugar & distillery sales.Sugar Further, sugar production for Balrampur Chini sales was aided by higher domestic quota & in 2019-20 sugar season not increased exports in Q1. the company has sold 2.9 lakh despite higher sugarcane availability. The tonnes of sugar in domestic market & 0.6 lakh company has been able to sacrifice sufficient tonnes through exports. The higher distillery sugar quantities through the production of B sales was driven by higher volumes as the heavy molasses. We believe the company is company commissioned 160 KLD new in a position to liquidate its current season distillery realisation due to higher proportion of which is far better position than industry (it B heavy ethanol also helped growth. Power would be carrying just a months in inventory sales was down by 13.5% to ₹ 95.7 crore compared to average 5 months inventory by mainly on account of lower volumes as industry). The company would see higher company has sold some quantities of bagasse distillery volumes with full year of new distillery power operations & higher ethanol realisation with realisation have remained down given revision more diversion towards B heavy ethanol. in power tariffs last year. Operating profit Balrampur chini is most efficient sugar increased by 23.9% to ₹ 217.9 crore with company in India with no high cost long term higher sugar & ethanol sales during the debt & least working capital debt requirement.



Amber Enterprises

of ₹24 crore at bottomline.

Amber Enterprises' Q1FY21 revenue declined Despite being a strong quarter, RAC industry by 79% YoY, while company reported a loss faced challenges in Q1 due to lower volume offtake amid lockdowns. As a result, Amber Enterprises also faced a sales loss of almost 40 days in Q1FY21. On the operating front, while gross margin remain flat on a YoY basis, Amber reported loss at EBITDA level to ~₹6 crore mainly due to low operating leverage. We await management commentary on future outlook of demand recovery in RAC industry as well as business opportunities under Atmanirbhar Bharat schemes



Majesco

signed an amended agreement to sell its 74.07% stake in the US entity (Majesco US). company to a private equity (Thoma Bravo, Hence, based on the stake, the company will LP) at a revised price of US\$16/share (from now receive cash of US\$513.8 million (₹ earlier offer of US\$13.1/share), valuing the 3853.3 crore). Assuming a capital gains tax, company at US\$729 million (~₹5,467 crore). the company would receive cash of ~₹3121.2 The increased offer from Thoma Bravo and crore. This, coupled with cash of ₹23.5 crore the amendment followed Majesco's receipt of on the company's balance sheet, the total an unsolicited acquisition proposal from an cash with the firm now would be ₹3144.7 crore unaffiliated third party. The company is now or ~₹ 1037/share (vs earlier ₹852/share). The valued at 5x FY20 EV/sales.

Majesco US (the US listed company) has Majesco India (the India listed company) holds company plans to distribute this cash via buyback and/or dividend. Hence we remain positive on the stock.





Ministry of defence (MoD) announced import The embargo list is in line to reduce imports Defence Manufacturi embargo list of 101 defence items to be and push the 'Make in India' and 'Atmanirbhar progressively implemented between 2020 to Bharat' initiative through 2024 to boost indigenization of defence development adopting technologies companies or production providing big push to "Atmanirbhar designed and developed by DRDO. The Bharat" and "Make in India" Initiatives. This estimated embargo list to enable estimated ₹ was one of the major steps proposed in Draft 4.0 lakh crore worth of contracts to be placed Defence production and Export Promotion on domestic industry over next 5 to 7 years policy (DPEPP) 2020. The decision offers a which comes to average contracts of ₹57000 great opportunity to Indian defence industry to crore to \$0,000 crore per annum. This would manufacture the items in the negative list by provide significant thrust using their own design and development manufacturing companies in scaling up their capabilities or adopting technologies designed production capabilities in the long term. In our coverage universe, companies & developed by DRDO. Bharat Electronics (BEL) and Cochin Shipyard (CSL) having strong indigenous capabilities in products like artillery systems, subsystems, Aerospace, Radars, Electronic warfare systems, shipbuilding etc. are likely to benefit from the move in the long run. Mastek Majesco US (the US listed company) has Mastek hold ~20 lakh shares in Majesco US. signed an amended agreement to sell its Based on the revised price, the company will company to a private equity (Thoma Bravo, receive additional ₹45 crore which is ~3% of LP) at a revised price of US\$16/share (from the company's market cap. earlier offer of US\$13.1/share), valuing the company at US\$729 million (~₹5,467 crore). The increased offer from Thoma Bravo and the amendment followed Majesco's receipt of an unsolicited acquisition proposal from an unaffiliated third party. The company is now valued at 5x FY20 EV/sales. Telecom The Supreme Court will examine whether the Assuming 15 years payment timeline (as insolvency proceedings of bankrupt telcos requested by telcos) at 8% interest rate, we Sector Reliance Communications (RCom), Aircel and expect annual instalments of ~₹ 6000 for Videocon Telecom are bonafide, while an Vodafone Idea and ₹ 3000 crore for Airtel. order on the timeline of staggered payments While for Airtel, it is very much within the (already reserved) of adjusted gross revenue-lability, we expect a meaningful case of (AGR) related dues is also likely. Vodafone Idea's long term survival only when substantial there capitalisation promoters/ strategic partners and/or change in regulations such as floor tariff norms, lowering of levies etc EV The Delhi government has issued Delhi The 3-year policy has set forward aggressive Indian Electric Vehicle Policy 2020, which envisages goals (25% of all new registrations to be space battery EVs forming 25% of all new electric, 50% of 2-W delivery fleet and 50% of registrations by 2023. The policy provides state procured buses to be electric). The upfront purchase incentives for all categories purchase incentives are over and above of vehicles (\$5,000/10,000 per kWh for 2W and FAME-II incentives, with certain unique PVs respectively and ₹ 30,000/unit for e-|benefits like waiver of road tax. It plans to fund auto's, e-rickshaws and goods carriers). the incentives through a fee-bate system thereby imposing additional taxes on petrol & diesel powered vehicles. The policy would help the fledgling EV ecosystem in India.



Midhani	defence industry, the government has announced restriction on import of 101 weapons and military platforms including wheeled armoured fighting vehicle (AFV), bullet proof jackets, light combat aircraft (LCA)		
	implementation of emission norms for tractors (TREM) and construction equipment (CEV) to October 1, 2021 and April 1, 2021 respectively	This will delay the increase in initial ownership costs for the >50 hp tractor segment as well as construction equipment. It will enable demand recovery as economic sentiments gain momentum and is positive particularly for Escorts with Tractor and Construction Equipment being its key domain.	
Bharat Forge	embargo on 101 items beyond given timelines (largely Dec 2020) to boost indigenisation of defence production. The list includes artillery guns, calibre guns as well as Armoured	In the defence space, the company has developed a manufacturing ecosystem for artillery guns. It is also currently executing a US\$ 100 million contract for manufacturing of Barak 8 missile kits with its Israeli partner under a JV i.e. Kalyani Rafael Advance Systems (KRAS). The company has also developed certain protective vehicles for Indian defence forces. Thus, the company is well placed with requisite capabilities to capture the opportunity offered under increasing domestic procurement by the Indian defence sector.	
	for 56.6% (on fully diluted basis) in troubled CG Power & Industrial Solutions. The investment is all primary shares issuance with	The bid values CG Power at ~0.4x price to sales (FY20 sales at ₹3,169 crore). TII has been on the lookout for inorganic growth opportunities in the post Covid environment, however with cash and investments of just ~₹180 crore on books as of FY20, a successful bid would likely be majority debt funded. Possible acquisition of CG Power would help the engineering division at TII.	\Leftrightarrow

Key developments (Continued...)

- Shree Cement has a strong presence in the north. We expect lowest decline in volume (down 20.9% YoY) to 4.8 MT after Sagar Cement on a like to like basis. Strong realisations (up 1.7% YoY) would provide some cushion. Thus, we expect revenues to fall only 21.4% YoY to ₹ 2386 crore, which is the lowest de-growth in the Industry. Strong realisations should help the company maintain highest EBITDA/t in industry at ₹ 1361/t. On an absolute basis, we expect EBITDA to decline ~28% YoY only to ₹ 652 crore
- For TTK Prestige, we expect revenues to decline by 57% YoY to ₹ 164.1 crore in Q1FY21. Owing to negative operating leverage, we expect TTK to report EBITDA and PBT loss of ₹ 20.2 crore and ₹ 24.5 crore, respectively
- Covid-19 breakout would make business growth remain sluggish for Bank of Baroda. We expect loan growth to dip to ₹ 6.9 lakh crore, up 1% QoQ with major traction towards MSME loans due to the ECLGS scheme. Incremental disbursements towards corporate & MSME is seen reducing margins though providing balance sheet growth ahead. Easing of the lockdown and streamlining of the moratorium opt in process may lead to a reduction in the moratorium book by ~5-10% from current levels of 65%. NII is seen at ₹ 6860 crore with NIMs at 2.65%. On the back of standstill account classification, asset quality is expected to stay stable with GNPA at 9.67%. Nationwide lockdown and IBC suspension may delay the breather for the bank's substantial NCLT exposure. As the bank has adequately provided for Covid-19 and the merger process nearing completion, credit cost is seen at 61 bps. We estimate PAT would come in at ₹ 702 crore
- CSL resumed production activities from May 6 at the Kochi unit (90% of turnover). Business was impacted on account of supply chain issues, delay in operational projects & lockdown. Taking cognizance of the above, we expect a 45% decline in CSL's Q1FY21E revenue, estimated at ₹ 400.9 crore. We expect employee expenses at normal levels as CSL has paid full salary to all the direct employees during the lockdown period. EBIDTA is expected at ₹ 38.1 crore, implying an EBIDTA margin of 9.5% vs. 19.3% YoY. There will be no additional impact of liquidated damages for operational projects as the company has invoked Force Majeure clause available in all the contracts. Absolute PAT is expected at ₹ 34 crore, down 72% YoY
- Ipca Labs Q1FY21E revenues are expected to grow 19% YoY to ₹ 1288 crore mainly due to strong overall growth. Domestic formulations are expected to grow 11% YoY to ₹ 503 crore on the back of one-off hydroxychloroquine (HCQS) opportunity. Export formulations are also expected to post robust growth of 43% to ₹ 350 crore mainly due to low base effect and one-time opportunity for HCQS in US and other markets. Similarly, the API segment is also expected to benefit from chloroquine based opportunities in the quarter. EBITDA margins are likely to improve 172 bps YoY to 20% mainly due to higher gross margins. Net profit is expected to increase ~39% YoY to ₹ 180 crore
- For Q1FY21E, We expect KEC International's revenues to de-grow 35.1% to ₹ 1566.5 crore. EBITDA is expected to decline 51.4% to ₹ 122.1 crore with EBITDA margin expected to see impact of 250 bps to 7.9% YoY. PAT is expected to decline 74.1% to ₹ 22.9 crore. KEC has announced new orders worth ₹ 1192 crore as on date for the quarter. For Q1FY21E, however, some deferred revenues of Q4FY20 may get booked in this quarter. International markets of KEC such as Brazil, Mexico, Dubai are expected to fare better than domestic markets
- Gabriel India reported muted Q1FY21 numbers. Net sales declined 76% YoY to ₹ 123 crore in the Covid impacted quarter, with top line performance impacted by sharp ~70% decline in auto sector volumes during the period and lower exposure to the aftermarket channel (~12% of sales). Loss at EBITDA level amounted to ₹ 17 crore while Loss after tax stood at ₹ 24 crore vs. profit of ₹ 22 crore in the base quarter
- Wonderla Holidays reported NIL operating revenue for the quarter due to complete shutdown of theme parks. Net losses, however, restricted to ₹14.51 crore led by sharp cut down in operating costs from ₹49 crore LY to ₹ 11.9 crore in the current quarter
- Life Insurance Business data for July 2020 shows that Industry APE de-grew 0.4% YoY to ₹ 7083 crore as against a growth of -45% in March 20 and 13% growth in July 2019. During the same period, LIC reported APE growth of 2.1% YoY to ₹ 3563 crore while private insurers reported APE de-growth by 2.9% YoY to ₹ 3521 crore. On an Individual APE basis, as on July 2020, industry reported flattish YoY growth to ₹ 5813 core with LIC at ₹ 2605 crore (up 10% YoY) and other private players at ₹ 3208 crore (down 7% YoY)
- As per AIOCD data, Indian pharma market (IPM) growth drops down to 0.2% in July 2020 after exhibiting a growth of 2.4% in June 2020 amid continued Covid-19 impact. Cardiac therapy grew 13.1% (vs June 13.9%), Anti-diabetic grew 5.9% (vs 8.5% in June) whereas Respiratory de-grew 2% vs 4.2% growth in June. Anti-infectives continue to be impacted with 10.2% de-growth (vs -9.7% in June) whereas Vitamins maintained their growth track of 5.5% (vs 5.7% in June)
- As per media sources, Tiger Global is looking to invest US\$100 million with an option to inject another US\$100 million ahead of its proposed IPO next year. This funding will value the company at US\$3 billion. We have valued the company at US\$4 billion
- Bhel has commenced civil works at 660MW Sagardighi supercritical thermal power plant in West Bengal. Valued at approximately ₹ 3500 Crore, the turnkey order for Sagardighi Thermal Power Project Extension Unit-5 was won by BHEL against stiff international competitive bidding (ICB) from West Bengal Power Development Corporation (WBPDCL)

•

Key developments (Continued...)


- Dabur announced the expansion of its baby care portfolio with the launch of eight new Ayurveda-based products looking into the growing demand of baby care products. It has launched the new baby care products on e-commerce platform Amazon, where these would be exclusively available
- As per media sources, out of the total ₹ 90000 crore discom liquidity package, ₹ 68000 crore has been sanctioned by PFC & REC. UP tops the chart for seeking the highest credit under the package so far at ₹ 20,000 crore followed by Telangana (₹ 12,000 crore), Karnataka (₹ 7,000 crore), Andhra Pradesh (₹ 6,000 crore), Maharashtra (₹ 5,000 crore). Punjab, Rajasthan and Jammu & Kashmir have sought around ₹ 4,000 crore each
- As per USFDA disclosures, Lupin has initiated a class-II recall of 11688 bottles of Lisinopril tablets (10 mg) from US. The drug, indicated for the treatment of high blood pressure, is being recalled due to presence of foreign tablets. The drug was manufactured at the company's Nagpur facility
- As per USFDA disclosures, Sun Pharma has initiated a class-III recall of 3516 bottles of its antiepileptic drug, Clonazepam tablets from US. The drug is being recalled due to cross contamination with other products
- In an update to earlier exchange disclosures, Alembic Pharma has approved the QIP allotment of 80,47,210 shares at the issue price of ₹ 932 per share, which is at a 4.97% discount to the floor price (₹ 980.75) as per SEBI regulations, to raise capital of ~₹ 750 crore
- Coal India (CIL) has revised its production target to 650-660 million tonnes for the current fiscal in the wake of the disruptions caused by the COVID-19 pandemic. The CIL had earlier set a production target of 710 million tonne for FY21
- Info Edge has completed QIP amounting to ₹ 1875 crore (~5% of market cap) at a share price of ₹ 3,090 per share (~7% discount to current price) and issue of ~60.6 lakh shares
- Industrial Bank has informed exchanges that it has acquired 56.8 lakh shares of Eveready Industries (~7.8% stake) and 78.3 lakh shares of McLeod Russel India Ltd (~7.5% stake) via invocation of pledged shares.
- ICRA has reaffirmed AA/Stable rating to Motilal Oswal's NCD Programme worth ₹ 200 crore
- Bombay high court will hear broadcasters' petition against NTO 2.0 implementation on 10 or 11 August. Trai has assured no action will be taken against broadcasters till the case is heard by the court
- Brickwork Ratings has downgraded Zee Entertainment's non-convertible preference shares and issuer rating to BWR AA- with credit watch with negative implications
- PVR has allotted 38.2 lakh rights equity shares at a price of ₹ 784 amounting to a total sum of ₹ 300 crore
- The board of Minda Industries would meet on August 11 to consider rights issue worth ₹ 250 crore



Nifty Weekly Chart NIFTY [N59901]11214.05, 1.27% IRIS Loa Price 12000 11500 11214.0 10500 10000 9500 9000 8500 8000 Source: www.SpiderSoftwareIndia.Com Stoch(5,3,5,3) Weekly Stochastic reacting lower from overbought teritorry signalling consolidation 50.00 A''S''O'N''D'20:JF'M'A''M'J''J'''A D'19:JFM"A'M''J"J 18: A S O N Wkl

Pivot Points						
		01	6.1			D.C.
Index/Stocks	Trend	Close	S1	S2	R1	R2
SENSEX	Neutral	38040.6	37848	37657	38171	38301
Nifty 50	Neutral	11214.1	11160	11106	11250	11286
ACC Ltd	Negative	1397.2	1385	1373	1416	1435
Axis Bank Ltd	Neutral	433.3	427	422	437	442
HINDALCO INDS	Positive	177.6	175	173	179	181
SBI	Negative	190.7	190	188	192	194
HINDUSTAN PETRO	Neutral	213.6	209	205	220	227
MUTHOOT FINANCE	Neutral	1217.0	1193	1170	1237	1258
Tata Motors	Positive	119.1	116	114	120	122
MRF LTD	Positive	62702.8	61548	60394	63558	64414
BAJAJ AUTO LTD	Negative	3001.7	2979	2955	3023	3043
TCS	Positive	2295.4	2278	2262	2319	2344
ITC LTD	Positive	196.1	195	193	198	199
CIPLA LTD	Neutral	728.7	722	716	738	746
PIRAMAL ENTERPRI	Positive	1464.2	1440	1415	1505	1545
Reliance Industries	Neutral	2146.5	2124	2103	2162	2179
BHARTI AIRTEL	Neutral	560.8	555	548	566	570
EQUITAS HOLDINGS	Positive	51.0	50	50	52	52

Nifty Call – Put Strike (Number of shares in lakh) – August 2020



Technical Outlook

Equity benchmarks edged higher amid ongoing earnings season as Nifty settled at 11215, up 1.3% or 142 points for the week. In the coming session, we expect the index to hold Friday's low (11142) and trade with positive bias and head towards 11300 levels. Thus, intraday dip towards 11200-11220 should be used to create long position for target of 11312.

We reiterate our stance of an outperformance of broader markets while Nifty undergoes a healthy consolidation in the broad range of 10900-11400. Such a consolidation will make price structure more robust as indices will re-establish a higher base which will act as a launch pad for next major up move. Hence, any dip from hereon should not be construed as negative, instead be capitalised as incremental buying opportunity in quality midcap and small caps to benefit from their outperformance.

CNX Nifty Technical Picture						
Nifty 50	Intraday	Short Term				
Trend	Up	Range Bound				
Support	11170-11140	10900				
Resistance	11250-11295	11400				
20 day EMA	0	10899.0				
200 day EMA	0	10586.0				

Advances/Declines							
	Advances	Declines	Unchanged				
BSE	1631	1074	148				
NSE	1194	663	112				

Daily Technical Calls Daily Technical Calls

- 1. Buy Bharat Forge in the range of 410.00-412.00
- 2. Buy Pidilite in the range of 1380.00-1384.00

All recommendations of August Future

See Momentum Pick for more details

Intraday Derivative Strategy

i) Britannia	
Buy BRIIND AUG Fo	ut at ₹3937.00-3940.00
CMP: 3940	
Target 1: 3968.5	Target 2: 4013.5
Stop Loss: 3908.5	

ii) Petronet LNG Sell PETLNG AUG Fut at ₹245.00-246.00 CMP: 245 Target 1: 243.5 Target 2: 240.5 Stop Loss: 247.5

See Derivatives view for more details



A Cho	9) Son									
Results	/Events Calendar										
27	July Monday	28	July Tuesday	29	July Wednesday	30	July Thursday	31	July Friday	01	August Saturday
United Sp Bharti infr Kotak Ma	narat Elec.,Escorts irits,Havells India atel,Pfizer,Tech Mah. hindra Bank,VGuard hid,Orient Electric	Orient Ce Sunteck F Oriental F	FC First,Hexaware m.,Quess Corp Realty,NIIT Tech,Castrol lotels,InduInd Bank Cement, Sanofi	Mahindra Lifespace,SIS Dr.Reddy,GSK,Bharti Airtel		Dabur, JM Fin., Tata Comm., HDFC Ltd., Torrent Pharma Mahindra Logistics, Apcotex Ajanta Pharma, Essel Propack Dhampur Sugar, Hester Bios		IOC,Bluedart,Tata Metaliks Jagran Prakashan, SBI,MOSL Sun Pharma, Zydus Wellness Tata Chemicals,Tata Motors Saregama,Teamlease		Relaxo F	ootwear
03	August Monday	04	August Tuesday	05	August Wednesday	06	August Thursday	07	August Friday	08	August Saturday
Exide Indo Bank of In UK Manuf	Kansai Nerolac ustries	Taj GVK I Gujarat G Narayana	•	Wednesday Diy Birla Soft, Inox Leisure Cadila Healthcare, Adani Gas Jyothy Labs, Hawkins Cooker Dwarikesh Sugar, Apollo Tyres JK Lakshmi cement		HPCL,GSPL,JK Tyre Gujarat Pipavav Port,Lupin VSSL,Sumitomo Chemicals Torrent Power,Indian Hotels Pidilite Ind.,Vodafone Idea		TV Today,Balrampur Chini Mahanagar Gas,Ramco Cem. Container Corp.,DCB Bank Kajaria Cera.,Sobha Ltd.,Bata M&M,Cipla,Gabriel Ind,Abbott		DCB Bank Divi's Labs Affle India Wonderla Holidays	
10	August Monday	11	August Tuesday	12	August Wednesday	13	August Thursday	14	August Friday	15	August Saturda
TTK Pres	tige,Bank of Baroda	Indoco Re	medies,Symphony	Ashok Le	yland,Bharat Forge	Tata Steel,DB Corp,APL Apollo		United Breweries,Voltas		JP GDP	QoQ
Sonata So	oftware,Shree Cement	AIA Eng.,	Somany Ceramics	Graphite	Graphite Ind.,Brigade Ent.,Eclerx Eicher Motors,Greaves Cotton		Berger Paints,Glenmark				
Titan ,IPC	A Labs,KEC Int.,HEG	VST Tillers Tractors,Bosch Ltd.				Hero Mot			Hindalco, Elgi Equip., Indian Bar		
Action Co	nst.,Caplin Point	Ador Wel	ding,Bajaj Electricals	Gulf Oil Li	ubricants,Aster DM	M Engineers Ind.,Trent.,Timken		Greenply	Industries,NESCO		
Triveni Er	g.,Cochin Shipyard	Ashoka B	uildcon,Ratnamani	Natco Pharma, Thermax		Shankara ,City Union Bank		Bodal Chemical,Sun TV			
17	August Monday	18	August Tuesday	19	August Wednesday	20	August Thursday	21	August Friday	22	August Saturday
Hind Rect		KNR EU Curren			EU Construction Output		EU Manufacturing PMI		ł	facuring PMI	
	ial Production MoM ve Assets	JP Export JP Trade	s, JP Imports Balance	UK CPI (YoY) EU CPI (YoY)		JP Manuf	Inufacturing PMI EU Services PMI UK Retail Sales (MoM) US Manufacturing PMI		EU Cons	sumer Confid.	
24	August	25	August	26	August	27	August	28	August	29	August
	Monday		Tuesday		Wednesday		Thursday		Friday		Saturday
UK Retail	Sales(MoM)	US Consu	umer Confidence	1	rial Profit (YoY)	US GDP	y Supply YoY	US Good EU Consi US Perso	onal Income s Trade Balance umer Confidence onal Spending umer Inflation Exo		

Date	Event	Country	Period	Actual	Expected
Date	Event	Country	Period	Expected	Previous
11-Aug	Unemployement Rate	UK	June	4.2%	3.9%
11-Aug	Industrial Production(YoY)	IN	July	-18.7%	-18.3%
11-Aug	Manufacturing Output	IN	June		-22.40%
11-Aug	PPI (MoM)	US	July	0.3%	-0.2%
12-Aug	GDP (YoY)	UK	June	-22.5%	-1.7%
12-Aug	Manufacturing Production	UK	June	10.0%	8.4%
12-Aug	CPI (YoY)	IN	July	6.2%	6.1%
12-Aug	Core CPI (MoM)	US	July	0.2%	0.2%
12-Aug	Crude Oil Inventories	US	July		-7.737M
13-Aug	Initial Jobless Claims	US	July	1,140K	1186K
13-Aug	Industrial Production(YoY)	CH	July	4.7%	4.8%
14-Aug	WPI Inflation (YoY)	IN	July	-1.1%	-1.8%

СН

IN

US

US

IN

-0.6%

3.0%

1.8%

0.5%

-0.79B

5.4%

7.5%

534.57B

July

July

July

July

July

Company Crore	Revenue Q1FY21E	•	•	EBITDA Q1FY21E	Chg(%) YoY	QoQ	PAT Q1FY21E	Chg(%) YoY	QoQ
Bank of Baroda	6,860.0	-2.4	0.9	5,152.6	-3.4	0.6	702.3	-4.7	38.6
Coachin Shipyard	400.9	-45.5	-50.9	38.1	-73.1	-76.6	34.0	-71.7	-75.5
KEC International	1,566.5	-35.1	-57.3	122.1	-51.4	-67.1	22.9	-74.1	-88.1
Shree Cement	2,385.8	-21.4	-25.8	651.9	-27.7	-39.6	155.6	-57.1	-73.5
Titan Company	1,980.9	-61.5	-58.2	-7.5	PL	PL	-89.6	PL	PL
TTK Prestige	183.6	-57.7	-52.1	-20.2	PL	PL	-24.5	PL	PL
IPCA Labs	1,287.8	19.4	19.9	257.6	30.7	52.9	180.0	38.9	109.3

Recent Releases	;
Date	Report
August 09,2020	Result Update- Cipla Ltd.
August 09,2020	Result Update - Divi's Laboratories
August 09,2020	Result Update - Lupin
August 09,2020	Result Update – Bata India
August 09,2020	Result Update – Mahindra & Mahindra

14-Aug Trade Balance 14-Aug Industrial Production (MoM)

14-Aug Exports

14-Aug Retail Sales

14-Aug FX Reserves

Major Economic Events this Week





Pankaj Pandey

Head – Research pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC Andheri (East) Mumbai – 400 093 research@icicidirect.com



Disclaimer

ANALYST CERTIFICATION

I/We, Pankaj Pandey, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INHooooooggo. ICICI Securities Limited SEBI Registration is INZooo183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc. as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eliqible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.